TB-500: What the Evidence Actually Shows

Search "TB-500" and you'll find it described almost interchangeably with thymosin beta-4 — sold as a healing peptide for tendons, ligaments, and muscle, often paired with BPC-157 in a "stack." What most of that marketing skips is a precise fact worth stating up front: TB-500 is not thymosin beta-4. It is a synthetic, N-terminally acetylated version of a 7-amino-acid piece of that 43-amino-acid protein — a different, much smaller molecule, sold under a name that borrows its parent's identity. That distinction, verified directly against the chemistry literature rather than assumed, shapes almost everything else in this article.

What TB-500 actually is

Two independent laboratory papers — one run for equine doping control, one for human doping control — first identified what's actually in a TB-500 vial. Both agree: it is the N-terminal acetylated 17-23 fragment of thymosin beta-4, written Ac-LKKTETQ, synthesized on its own rather than expressed as part of the full protein⁴. The seven residues in that fragment — LKKTETQ — are described in the same literature as "the active site within the protein thymosin β4 responsible for actin binding, cell migration and wound healing⁵." That's the whole basis for TB-500's marketing: it's built on the piece of Tβ4 believed to do the cell-migration work, extracted and sold as its own product, with an acetyl group added to the front end that the natural protein's fragment wouldn't otherwise carry on its own.

That is a real, chemically verifiable relationship — not a fabricated one. It is also not the same thing as "TB-500 is thymosin beta-4," which is how it's marketed almost everywhere. A 2026 sports-medicine review makes the same distinction independently, in its own list of covered peptides: it names "Tβ4 (thymosin beta-4)" and "TB-500 (thymosin beta-4 fragment)" as two separate entries, not one¹. This article follows that same separation throughout, because — as the next two sections show — the evidence behind each of those two names is not the same evidence.

What the animal evidence actually shows

The literature specifically testing TB-500 itself, rather than the full Tβ4 protein it's derived from, is thin — much thinner than BPC-157's. A direct PubMed search for "TB-500" returns 17 total results, and outside of two narrative reviews, nearly every one of them is an analytical-chemistry or doping-detection paper, not an efficacy study. Two results are worth reporting directly because they're the actual TB-500-specific data this article could locate:

• •Rat Achilles tendon repair, 2026. A Turkish orthopedic-surgery group ran the only dedicated TB-500 efficacy study found in this review: 32 rats underwent standardized Achilles tendon transection and repair, then were split into four groups of eight — control, BPC-157, TB-500, and a combination — with four weeks of daily intraperitoneal dosing before biomechanical and histological analysis. The TB-500 group showed a statistically significant increase in the tendon's maximum load to failure compared to control (p<0.05), along with significantly better histopathological scores for tendon architecture and collagen organization⁷. That's a real, specific, dose-tested finding — in rats, on a surgically transected and repaired tendon, with the study's own authors describing it as "exploratory" and "preliminary," explicitly pending dose-optimization and longer studies. One more detail from that same study, directly relevant to how TB-500 is actually sold: combining BPC-157 and TB-500 did not outperform either peptide given alone — worth knowing if you've seen the two marketed as a stack on the premise that they compound each other's effect.
• •In vitro wound-healing screen, 2024. A Korean doping-control laboratory ran the other TB-500-specific study located here, and its finding complicates the marketing case rather than supporting it. The study's own stated premise, before it even ran the experiment: "The biological effects of TB-500...have not been documented." Its own result, testing TB-500 and its breakdown products head-to-head in a fibroblast wound-healing assay: only one metabolite, called Ac-LKKTE — not TB-500 itself — "showed a significant wound healing activity compared to the control." The study's own conclusion states this "suggest[s] that the previously reported wound-healing activity of TB-500 in literature may be due to its metabolite...rather than the parent form⁶." Put plainly: the one cell-culture study that actually isolated TB-500 from its own breakdown products found that TB-500 itself wasn't the active ingredient — something it turns into after dosing might be.

Everything else cited for TB-500's healing claims — angiogenesis, keratinocyte migration, collagen deposition — traces back to studies of the full-length Tβ4 protein, not the fragment⁵. That's not necessarily wrong to reference, but it is a different molecule, and neither of the two reviews surveying this exact literature treats that substitution as settled: one calls the preclinical case "promising" while stating plainly "there is a current lack of clinical trials³," and the other is more direct still — "TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking²."

What the human evidence actually shows

This is the shortest section in this article because the evidence is, as of this review, essentially absent. The direct PubMed search above found zero published human clinical studies, case reports, or case series of the TB-500 fragment specifically. Not thin — zero. Every review that has looked for it says the same thing in its own words: "human orthopaedic data are lacking²"; "a current lack of clinical trials³"; "rigorous human safety data are scarce¹."

A search of ClinicalTrials.gov for "TB-500" returns exactly one interventional-trial record — and that record's own summary field states, verbatim, "This fictional study is an example of a ClinicalTrials.gov-style record." It is not a real trial, by its own description, and this article does not treat it as one.

Here's where the identity distinction from the first section matters most: search ClinicalTrials.gov instead for "thymosin beta-4" — the full-length protein — and a real, decades-long human trial program appears. Completed Phase 2 trials tested it in venous stasis ulcers and in chronic dry eye (the latter under the commercial name RGN-259, across multiple completed trials). Completed Phase 1 studies checked its safety and pharmacokinetics in healthy volunteers. Two more trials, in corneal wounds and in epidermolysis bullosa, were terminated — but for recruitment and drug-supply logistics ("slow recruitment"; "lack of patient availability and expiration of study drug"), not because either trial reported the drug didn't work or wasn't safe, a distinction worth being precise about rather than letting "terminated" imply a negative result it didn't report. That trial record is real. It also belongs entirely to the full 43-amino-acid Tβ4 protein — not to the acetylated 7-residue fragment sold as TB-500. None of it is evidence for TB-500 specifically, and this article does not borrow it as such.

The current FDA and anti-doping status

TB-500 has never had an FDA-approved drug product — a direct, live check against DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns zero results for both "TB-500" and "thymosin." Its compounding status has moved recently and is still unsettled. FDA placed TB-500 in Category 2 of its interim 503A bulk-substances list — substances presenting significant safety risks that pharmacies should not compound — in 2023. On April 15, 2026, FDA removed TB-500 from Category 2, alongside eleven other peptides including BPC-157, because the original nomination was withdrawn — a procedural removal, not an FDA safety finding, and one that does not by itself make compounding TB-500 legal. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee formally reviewed "TB-500-related bulk drug substances (TB-500 (free base)/TB-500 acetate)" for inclusion on the 503A Bulks List, with FDA's own reviewed-use column reading "Wound healing." The committee voted 8-6, with one abstention, to recommend TB-500 for inclusion. That is a recommendation, not a rule: FDA can accept, reject, or sit on a PCAC recommendation indefinitely, and formal notice-and-comment rulemaking has not started. Re-checked independently one day after the calculator page's own review, rather than assumed unchanged: it hasn't changed. TB-500 today has no approved product, no FDA-set dosing standard, and a compounding status that is recommended-but-not-finalized.

Separately, and more settled: TB-500 is described in the peer-reviewed sports-medicine literature as remaining a banned substance in competitive sport, alongside full-length Tβ4² — worth knowing regardless of where FDA's compounding review lands, for any reader who is a tested athlete.

What this means if you're considering a compounded TB-500 product

Put the pieces together and the picture is more sparse than most product pages suggest. The molecule actually sold as TB-500 is a specific, verifiable fragment of thymosin beta-4 — not the protein itself — and the literature testing that exact fragment is small: one 2026 rat tendon study showing a real biomechanical improvement, one 2024 cell-culture study whose own authors found the wound-healing activity may belong to a metabolite rather than TB-500 itself, and zero published human studies of any kind. The much larger, decades-old human trial record that gets implicitly borrowed in marketing belongs to a different molecule — full-length Tβ4 — and even that record includes two trials terminated for recruitment reasons before they could report an outcome either way.

None of that means TB-500 doesn't do anything; it means the specific claim "TB-500 heals tendons in people" currently has no published human evidence behind it, positive or negative, and the one head-to-head animal study available found that stacking it with BPC-157 — a common marketing pairing — didn't outperform either peptide alone. If you're weighing a compounded TB-500 product, that gap matters concretely: a study finding, animal or otherwise, describes what was in the syringe the researchers measured and controlled. It says nothing about the identity, purity, or concentration of a vial purchased from an unregulated seller under the same name — and, as the current regulatory status above confirms, there's no FDA-approved product or agency-set dosing standard to check that vial against. Our TB-500 reconstitution calculator does the vial-to-syringe arithmetic on the numbers you provide, without validating the product itself, for exactly that reason. Readers weighing BPC-157 specifically — the peptide most often stacked with TB-500 and the subject of the single animal study that tested both side by side — can find that molecule's own evidence record here.